Status not kept up to date
Safety and Feasibility of TWIICE Rise
NCT05926310 · TWIICE · Updated 8 Aug 2023
- What is being tested
- TWIICE Rise
- For
- Spinal Cord Injuries; Gait Disorders, Neurologic
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 70 years. About 15 people. The full rules are on the registry page.
- Where
- Switzerland
- When
- Starts or started 25 July 2023, ends June 2024. Registered 3 July 2023.
- Results
- None posted yet.
In the researchers' words
The aim of this study is to assess the safety and the feasibility of two versions of TWIICE Rise for exoskeleton-assisted ambulation in patients with a spinal cord injury. This study is done in two phases: The first phase evaluates the safety and feasibility of TWIICE Rise 0.0 with 5 patients over 6 sessions in clinic. The second phase is being conducted with TWIICE Rise 1.0. This version has potentially improved functionalities based on feedback from Phase 1. Safety and feasibility will be assessed with 10 patients over 24 sessions in different settings (clinic, home, and community environment).
Sites
- Swiss Paraplegic Centre NottwilNottwil, Canton of Lucerne, Switzerland